Onkologie. 2018:12(4):203-204 | DOI: 10.36290/xon.2018.037

Nab-paclitaxel in a long-term patient with metastatic pancreatic carcinoma

Beatrix Bencsiková
Masarykův onkologický ústav, Brno

Pancreatic carcinoma continues to be among tumors with high mortality. Systemic anticancer treatment did not bring any significant progress,however, there is a trend towards better therapeutic outcomes. For locally advanced inoperable and metastatic of the newer regimens ofFOLFIRINOX and the combination of nab-paclitaxel and gemcitabine have a very good effect and toxicity over long-term administration.

Keywords: pancreatic adenocarcinoma, nab-paclitaxel, chemotherapy

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bencsiková B. Nab-paclitaxel in a long-term patient with metastatic pancreatic carcinoma. Onkologie. 2018;12(4):203-204. doi: 10.36290/xon.2018.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Coveler AL, et al. Localised pancreatic cancer: multidisciplinary management. A, Soc Clin Oncol Educ Book 2016; 35: 217-226. Go to original source... Go to PubMed...
    2. Von Hoff, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703. Go to original source... Go to PubMed...
    3. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.